• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Athira Pharma, Inc. - Common Stock (NQ:ATHA)

    3.720 +0.010 (+0.27%)
    Streaming Delayed Price Updated: 11:16 AM EDT, Oct 16, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Athira Pharma, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Athira Pharma Announces Reverse Stock Split
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
    Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical... 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
    Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
    First-in-human, dose escalation study to evaluate safety, tolerability and pharmacokinetics in healthy volunteers with trial completion expected by year-end 2024 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Participate in Upcoming June Conferences
    Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second Half of 2024 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Participate in Upcoming May Conferences
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
    Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercialization 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
    Fosgonimeton counteracts mechanisms of amyloid-beta (Aβ)-driven toxicity and demonstrates neuroprotection in preclinical models of Alzheimer’s disease 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
    Presentation to highlight therapeutic potential of Athira’s small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and... 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
    Results demonstrate ATH-1105 is neuroprotective, preserves motor and nerve function and extends survival in preclinical models of ALS 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Sidoti Events, LLC's Virtual December Small-Cap Conference
    Via ACCESSWIRE
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.